Lilly Announces Strategic Collaboration with KeyBioscience AG

8 June, 2017

Lilly Announces Strategic Collaboration with KeyBioscience AG

Companies to Collaborate on Developing New Class of Diabetes Treatments

The collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089 and KBP-056. KeyBioscience has initiated Phase 2 development with KBP-042. Other assets included in the collaboration, engineered for differences in effect or potency, range from Phase 1 to pre-clinical.

Read the press release here

EULAR Conference 2017

7 June, 2017

The Nordic Bioscience Science Team will be at EULAR in Madrid from June 14-17. We are proud to have 12 accepted abstracts this year and together with good collaborators we will display the newest biomarker data within SSc, RA, PsA, AS and OA. Please reach out to Klaus Meyer Møller (kme@nordicbio.com) to set up a meeting with the team or stop by one of our posters at the conference.

Read the abstract titles here

ASCO Annual Meeting 2017

4 June, 2017

Today the Nordic Bioscience group is presenting the poster "EXTRACELLULAR MATRIX (ECM) PROTEIN FRAGMENTS IN SERUM AND OUTCOMES IN TWO METASTATIC BREAST CANCER COHORTS" at ASCO Annual Meeting 2017 in Chicago. We show that extracellular matrix (ECM) protein fragments in serum is predictive of outcome in two metastatic breast cancer cohorts. Please reach out to Louise Brink Thomsen (lbt@nordicbio.com) to set up a meeting with the team or stop by our poster at the conference.

Read the abstract and poster here

OARSI Conference 2017

7 May, 2017

With a total of 10 accepted abstracts we are proud to be at the OARSI meeting this week. Come and learn how to utilize biomarkers in pharmaceutical research and development at our 2 oral presentations and 8 posters throughout the conference. We will be happy to discuss biomarker strategies for evaluating joint health from early preclinical research to late stage clinical Development.

Read the abstracts here

REGAIN

6 October, 2016

 

NORDIC BIOSCIENCE JOINS NON-PROFIT CONSORTIUM TO CURE HEARING LOSS. As a part of our engagement in innovative science and unmet medical needs, the Nordic Bioscience Clinical Development division has entered into a non-profit EU-funded project, REGAIN, with a promising medical treatment for sensorineural hearing loss; the most common type of hearing loss. The REGAIN project aims to develop and clinically test a new medical treatment of hearing loss caused by the loss of sensory hair cells in the inner ear, in two early clinical trials in Europe. The trials will be managed by the trial expert team at Nordic Bioscience.

 

Read the press release here

BMS Collaboration

17 April, 2017

Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology

Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis (NASH)

 

Read the press release here

Litmus Consortium

24 March, 2017

We are very proud to be part of the LITMUS consortium, (LITMUS: Liver Investigation - Testing Marker Utility in Steatohepatitis) which was just awarded a prestigious IMI grant. The overarching aim of LITMUS is to develop, validate and advance towards regulatory qualification biomarkers that are able to diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. The ultimate goal is to establish a defined panel of biomarkers that, singly or in combination, enables detection and monitoring of disease progression/regression from NAFL through NASH to fibrosis and cirrhosis.

 

Read more about it here

 

Book Release

26 August, 2016

Together with Elsevier science, Nordic Bioscience have taken the time to condense all our collagen, elastin and laminin knowledge into one book. We are very proud of that the book focuses on biology and biomarkers of ECM and provides particular insights into collagens, laminins and elastin. We hope this will advance the interest and research of biomarkers in the ECM field associated with pathologies such as cancer, fibrosis and rheumatologic disorders.

An Intelligent Approach to Clinical Trial Monitoring

Many pharmaceutical companies are excited by Risk-Based Monitoring but are uncertain about how to implement such an initiative.

Nordic Bioscience has pioneered Risk-Based Monitoring since 2011 and our mission is to provide the industry with credible data that supports a change in the monitoring approach.

Recently, we published a review in the European Journal of Clinical Pharmacology that supports risk-based monitoring and concludes that reduced source data verification combined with a centralized, risk-based approach may be the solution to reduce monitoring costs while improving data quality.

Read the full publication here

Novel Biomarker Research

Nordic Bioscience to participate in EU funded ALD research project GALAXY

16 December, 2015

For the next 6 years, Nordic Bioscience will be part of the EU funded Alcoholic Liver Disease (ALD) research project GALAXY, which has a total budget of DKR 47 million. The aim is to find an easy and effective way to identify the people who do not know that they have the disease. Nordic Bioscience’s contribution is evaluation of our Protein Fingerprint biomarkers for early diagnosis, treatment monitoring, selection of patients for treatment and predictive for drug treatment response in patients with alcoholic liver disease.

Read the full press release here

Nordic Bioscience’s central and specialized laboratory services continue to grow

EU funded OA research project APPROACH

23 September, 2015 

For the next 6 years Nordic Bioscience will play a significant role in the EU funded osteoarthritis (OA) research project APPROACH, which has a total budget of EUR 15 million. The aim is to identify the patients most likely to respond to a given treatment using a validated biomarker drug development tool box for OA. Nordic Bioscience’s contribution is application of our validated proprietary Protein Fingerprint biomarkers, our FDA certified laboratory to ensure high quality and reproducibility of measurements, and regulatory approval process expertise.

Successful completion of phase I study

19 August, 2015

Together with our subsidiary KeyBioscience AG, we are proud to announce the successful completion of our phase I study with our novel Dual Amylin and Calcitonin Receptor Agonist (DACRA) that we currently are developing for type 2 diabetes, obesity and NASH. The DACRA KBP-042 is an insulin sensitizer which causes a significant weight reduction. The study confirmed tolerability of the molecule and more importantly indicated a substantial potential for treatment efficacy in the target population.